CLINICAL TRIAL / IRB19-0400

  • Recruiting
Eligibility Details Visit Clinicaltrials.gov

Contact Information

A Phase 3, Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE CM Trial) (Protocol Number: Eidos AG10 301)

Gender
Any

Age Group
Any

At a Glance

IRB#IRB19-0400

Lead PhysicianNitasha Sarswat

Collaborator(s)N/A

EligibilityRecruiting